- |||||||||| lacosamide / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Clinical Reasoning: A 73-Year-Old Woman With Episodic Dysarthria and Horizontal Binocular Diplopia. (Pubmed Central) - May 6, 2022 Our patient was started on lacosamide 50 mg twice a day with a notable decrease in symptom frequency. This case illustrates the importance of detailed clinical and electrodiagnostic studies in making the diagnosis of delayed radiation induced myokymia with episodic dysarthria and provides guidance on potential therapeutics.
- |||||||||| Rolling With the Punches: Management of Postictal Agitation () - May 5, 2022 - Abstract #APA2022APA_627;
His antiepileptic regimen was bolstered by adding lacosamide...We discuss the rationale for selection of agents in such cases in a stepwise manner, while maintaining the ever tenuous balance between excessive sedation and agitation control. Implications - Identification of risk factors can facilitate prompt diagnosis and treatment of PIP - PIP-associated agitation can be severe and effective management requires creative utilization of multimodal pharmacotherapy - Future directions should include best practice guidelines for management
- |||||||||| buspirone/melatonin (BCI-952) / BrainCells, lamotrigine liquid oral suspension / OWP Pharma
Medroxyprogesterone for Refractory Agitation in TBI and Parkinson’s Disease () - May 5, 2022 - Abstract #APA2022APA_549; Psychiatric course of treatment included adequate trials of Quetiapine, Olanzapine, Buspirone, Melatonin, Valproic Acid, Trazodone, and varying levels of benzodiazepines...Due to severity of his Parkinson''s, Neurology was reluctant to make changes to Carbidopa-Levodopa 25-100 mg four times daily due to the overall motor benefit he experienced...As in the prior case, he was started on medroxyprogesterone IM 150 mg weekly and found benefit at 300 mg weekly, which allowed for discharge to memory care unit. While dopamine and D2-like receptor families have been associated with impulsive personality traits, these cases illustrate the potential for Medroxyprogesterone to target an alternative mechanism when agitation appears refractory to treatment, and changes to dopamine may be unable to be made.
- |||||||||| Lennox-Gastaut Syndrome: A Case Report and Literature Review () - May 5, 2022 - Abstract #APA2022APA_525;
Therefore, it is important to understand the complexity in trying to provide symptomatic relief to LGS patients. Despite seeing the majority of cases lead to moderate - to - severe cognitive impairment within the first 5 years, targeting LGS and its surrounding neurocognitive problems individually and holistically, can improve the lives of the patients, but also in the lives of their families.
- |||||||||| levetiracetam / Generic mfg.
Journal: A Case of Possible Levetiracetam Induced Aseptic Meningitis vs Viral Meningitis. (Pubmed Central) - May 5, 2022 Applying the Naranjo Scale yields a score of 4, which indicates possible levetiracetam-induced meningitis in this adult patient. Providers should be cognizant when prescribing antiepileptics to assess and monitor for aseptic meningitis that may appear with atypical symptoms.
- |||||||||| lacosamide / Generic mfg.
Retrospective data, Journal, Monotherapy: Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes. (Pubmed Central) - Apr 29, 2022 Lacosamide appears to be efficacious and safe for achieving seizure freedom in patients with solitary viable parenchymal neurocysticercosis. Lacosamide showed good efficacy for controlling seizures with fewer adverse effects, and therefore may be a good candidate as a first-line medication for the treatment of new-onset CECTS.
- |||||||||| lacosamide / Generic mfg.
Journal: Late onset AMACR deficiency with metabolic stroke-like episodes and seizures. (Pubmed Central) - Apr 19, 2022 Lacosamide was continued for seizure prevention...Genetic peroxisomal disorders can present in older age; our patient is the oldest in the AMACR deficiency literature. Novel features in our case include central apnoea, dystonia and rapid eye movement behaviour disorder.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Preclinical, Journal: CRMP2 modulates mossy fiber sprouting in dentate gyrus of pilocarpine induced rat model of epilepsy. (Pubmed Central) - Apr 15, 2022 As a novel anti-epilepsy drug, Lacosamide is able to impair CRMP2 mediated tubulin polymerization...In addition, with the reduction of CRMP2 expression levels in dentate gyrus by CRMP2 shRNA, we observed decreased mossy fiber sprouting in these CRMP2 knockdown rats. Our results demonstrated that CRMP2 modulates mossy fiber sprouting in dentate gyrus of pilocarpine induced rat model of epilepsy.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. (Pubmed Central) - Apr 14, 2022 Additionally, compared with dose-normalized concentrations from control participants, pregnancy dose-normalized median (SE) concentrations decreased significantly by week of gestational age: carbamazepine, -0.14 (0.06) μg/L/mg (P = .02); carbamazepine unbound, -0.04 (0.01) μg/L/mg (P = .01); lacosamide, -0.23 (0.07) μg/L/mg (P < .001); lamotrigine, -0.20 (0.02) μg/L/mg (P < .001); levetiracetam, -0.06 (0.03) μg/L/mg (P = .01); oxcarbazepine, -0.14 (0.04) μg/L/mg (P < .001); oxcarbazepine unbound, -0.11 (0.03) μg/L/mg (P < .001); and zonisamide, -0.53 (0.14) μg/L/mg (P < .001) except for topiramate (-0.35 [0.20] μg/L/mg per week) and carbamazepine-10,11-epoxide (0.02 [0.01] μg/L/mg). Study results suggest that therapeutic drug monitoring should begin early in pregnancy and that increasing doses of these anticonvulsants may be needed throughout the course of pregnancy.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Retrospective data, Review, Journal, Monotherapy: Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. (Pubmed Central) - Apr 8, 2022 For people with generalised tonic-clonic seizures (with or without other seizure types), current first-line treatment sodium valproate has the best profile compared to all other treatments, but lamotrigine and eventrate would be the most suitable alternative first-line treatments, particularly for those for whom sodium valproate may not be an appropriate treatment option. Further evidence from randomised controlled trials recruiting individuals with generalised tonic-clonic seizures (with or without other seizure types) is needed.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members. (Pubmed Central) - Apr 5, 2022 Other relevant findings were that a minority of respondents ever prescribe AEDs in brain tumor patients without epilepsy solely as prophylaxis (29% [53/181]), but a majority routinely considers complete AED withdrawal in BTRE patients who are seizure-free after antitumor treatment (79% [141/179]). Our results show that among European professionals treating patients with BTRE levetiracetam is considered the first choice AED, with the presumed highest efficacy and least adverse effects.
- |||||||||| carbamazepine / Generic mfg.
Clinical, Review, Journal: Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review. (Pubmed Central) - Mar 31, 2022 Eslicarbazepine acetate, lacosamide, and perampanel improved or had no effect on sleep...Clonazepam, felbamate, lamotrigine, oxcarbazepine, and phenobarbital worsened or had no effect on sleep...Overall, cannabidiol, carbamazepine, and levetiracetam had no effect on sleep...Nonetheless, other ASMs may worsen sleep in some settings. Clinicians should consider such observations when making treatment decisions, particularly for patients with comorbid sleep disorders.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Cardiac effects of rapid intravenous loading of lacosamide in patients with epilepsy. (Pubmed Central) - Mar 30, 2022 Elderly patients or patients with underlying cardiac diseases were prone to exhibiting a more prolonged PR interval after IV loading of LCM. Thus, the loading dose of IV LCM should be infused under careful ECG monitoring in these patients.
- |||||||||| Clinical, Journal: Epilepsy in adults with neurodevelopmental disability - what every neurologist should know. (Pubmed Central) - Mar 29, 2022
Seizures with a co-morbid NDD should be considered as a collective complex clinical presentation and not discrete conditions. This seminar was co-designed, co-produced and co-authored by an expert by experience and includes case studies and a video to highlight what can go wrong and how it can be avoided.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo, lamotrigine liquid oral suspension / OWP Pharma
Preclinical, Journal: Simultaneous Determination of Lamotrigine, Oxcarbazepine, Lacosamide, and Topiramate in Rat Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry. (Pubmed Central) - Mar 25, 2022 The matrix effect was within 91%-105%, and the recovery was better than 88%. The established UPLC-MS/MS method was successfully applied to the pharmacokinetic study of lamotrigine, oxcarbazepine, lacosamide, and topiramate in rats.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Abdominal epilepsia partialis continua in a patient with astrocytoma treated with Lacosamide - value of repetitive EEG recordings. (Pubmed Central) - Mar 24, 2022 The independent spikes in her frontal and parietal regions suggested the presence of a large epileptogenic zone generating independent epileptiform activities in the pre-central motor cortex and the post-central sensory cortex as the pathophysiologic phenomena in persistent abdominal EPC. To the best of our knowledge, this is the first report presenting a patient experiencing an abdominal EPC due to a cerebral mass resolved with lacosamide suggesting this drug is a promising treatment option in resistant EPC.
- |||||||||| lorazepam / Generic mfg., midazolam hydrochloride / Generic mfg.
RAPIDLY PROGRESSIVE ANTI-NMDAR ENCEPHALITIS: MANAGEMENT CHALLENGE IN A PATIENT ADMITTED TO THE PICU ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_2082; She developed hypoxemic respiratory failure, requiring mechanical ventilation, midazolam drip and IV antibiotic/acyclovir prophylaxis without improvement of movements...Once infection ruled out, Solu-medrol was started...This case is uncommon, our patient developed acute respiratory failure, AKI, and bullous lesions over the first 48hrs of admission. Prompt immunosuppressive therapy and high index of suspicion for paraneoplastic mass as etiology of her autoimmune encephalitis, helped control refractory focal movements, skin lesions and frail state in a timely manner.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
HIGH-DOSE INTRAVENOUS PUSH LACOSAMIDE: SAFETY AND EFFICIENCY IN ADMINISTRATION ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1897; IV push administration of lacosamide 300 mg and 400 mg was associated with minimal adverse events and a relatively fast time from order verification to administration. The utilization of this route of administration has potential to reduce a patient’s time in status epilepticus without adding an increased risk of adverse events.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
EVALUATION OF INPATIENT STAT ANTIEPILEPTIC DRUG ADMINISTRATION DELAYS ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1789; This retrospective study evaluated patients who had one-time, “stat” or “now” orders for the following AEDs: fosphenytoin, lacosamide, levetiracetam, phenobarbital, and valproic acid from January 2019 to June 2021. Our findings add to the literature describing timeliness of AED administration in clinical practice and support the use of premix products whenever possible to avoid medication preparation delays.
- |||||||||| Fycompa (perampanel) / Eisai
Clinical, Journal, Real-world evidence: Real-world Analysis of Hospitalizations in Patients with Epilepsy and Treated with Perampanel. (Pubmed Central) - Mar 19, 2022 Although these were post hoc analyses of trials in older children (4-16 years of age), our results provide supportive evidence for the utility of the novel time-to-event trial design for future trials in infants and young children (1 month to <4 years of age). Perampanel was associated with a significant reduction in one-year hospitalization risk.
- |||||||||| Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Clinical, Review, Journal: Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. (Pubmed Central) - Mar 19, 2022 Overall, long-term lacosamide monotherapy was generally well tolerated up to 600 mg/day, with no new safety signals identified. Patients receiving FDA-RDMD of cenobamate were more likely to have ≥50% seizure reduction compared with FDA-RDMD of the seven assessed ASMs and branded ASMs, without an increase in treatment discontinuation due to TEAEs.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: A paediatric case of lacosamide-induced panniculitis. (Pubmed Central) - Mar 19, 2022 The mean PDDs of most AEDs were lower than the DDDs developed by the World Health Organization. No abstract available
|